Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2011
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
2009 StandoutNobel
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Treatment of kidney cancer
2009 StandoutNobel
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage
2008 StandoutNobel
Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor
2012
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis
2007
Hedgehog-Regulated Processing of Gli3 Produces an Anterior/Posterior Repressor Gradient in the Developing Vertebrate Limb
2000 Standout
Hedgehog and Patched in Neural Development and Disease
1998
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
2008
Natural products: An evolving role in future drug discovery
2011 Standout
Ovarian cancer
2014 Standout
Renal cell carcinoma
2009
Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count
2006
Temsirolimus in the treatment of advanced renal cell carcinoma
2007
Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio
2010
Neuroblastoma: biological insights into a clinical enigma
2003 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
The Hedgehog and Wnt signalling pathways in cancer
2001 StandoutNature
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Inhibition of Na+-Ca2+ exchange mechanism in cardiac sarcolemmal vesicles by harmaline
1987
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference
2009 StandoutNobel
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
2005 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
2006
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
2009
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
2009
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine
2000 StandoutNature
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
A Review of Integrated Staging Systems for Renal Cell Carcinoma
2012
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
A new patient‐focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options
2010
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
2009
Neuroblastoma
2007 Standout
NF-κB Activation Mediates Doxorubicin-induced Cell Death in N-type Neuroblastoma Cells
2001
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
2011
Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy
2012
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy
2007
Neutrophils in cancer: neutral no more
2016 Standout
Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?
2006
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
The Baseline Ratio of Neutrophils to Lymphocytes is Associated with Patient Prognosis in Rectal Carcinoma
2010
Purkinje-cell-derived Sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum
1999 Standout
Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?
2012
Cancer-related inflammation and treatment effectiveness
2014 Standout
Renal cell carcinoma
2017 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients
2011
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
2013
Treatment for renal cancer: are we beyond the cytokine era?
2006
The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis
2011
Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma
2012
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
2006
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.
2001
Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study
2005
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
2006
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
Prognostic Factors in Patients with Advanced Renal Cell Carcinoma
2004
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
2004
Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors
2005
Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma
2003
Decision aids for people facing health treatment or screening decisions
2017 Standout
Immunotherapy for renal cell cancer in the era of targeted therapy
2008
Correlation of Early Metastatic Response by123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma
2003
Small molecule modulation of Smoothened activity
2002 Standout
IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase
2006
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT
2007
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Immunotherapy for metastatic renal cell carcinoma
2007
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status
2006
Modern Trends in Hyperspectral Image Analysis: A Review
2018 Standout
Guideline for Management of the Clinical T1 Renal Mass
2009 Standout
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
2008 Standout
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
2005
Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma
2009
Sodium/Calcium Exchange: Its Physiological Implications
1999 Standout
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
2011 Standout
Targeted therapy for advanced renal cell carcinoma
2008
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of M Buclon being referenced
[Harmaline, an inhibitor of the process of intestinal transport associated sodium-ion transport].
1977
Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
2002
High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)
2001
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
2005
Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?
1998
LMCE3 Treatment Strategy: Results in 99 Consecutively Diagnosed Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis
2000
Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients
2003